HR Execs on the Move

Carepoint Pharmacy

www.carepoint.pharmacy

 
We offer a wide range of clinical services along with a comprehensive product line. Our professional team is on hand 24/7 to exceed your expectations.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

Monitored Therapeutics

Monitored Therapeutics Inc. is focused on solutions for the management of respiratory diseases like COPD, Asthma, Lung Transplant, and Cystic Fibrosis.

Madrigal Pharmaceuticals

Madrigal Pharmaceuticals is a clinical-stage biopharmaceutical company pursuing novel therapeutics that target a specific thyroid hormone receptor pathway in the liver, which is a key regulatory mechanism common to a spectrum of cardio-metabolic and fatty liver diseases with high unmet medical need. The Company has advanced its lead candidate, resmetirom, also known as MGL-3196, a first-in-class, orally administered, small-molecule, liver-directed, thyroid hormone receptor (THR) β-selective agonist, through Phase 2 clinical trials in NASH. Primary and key secondary endpoints were achieved including reduction of liver fat on a sensitive non-invasive imaging test, lowering of multiple atherogenic lipids including LDL-cholesterol and triglycerides, and resolution of NASH on liver biopsy. Based on evidence of broad activity and a favorable safety profile, Madrigal has initiated a Phase 3 clinical study in NASH patients with advanced liver fibrosis, MAESTRO-NASH, in which the primary endpoint after one year of dosing is resolution of NASH and key secondary endpoints include LDL-cholesterol lowering and reduction in liver fibrosis. Clinical benefit in reducing progression to more advanced liver disease, including cirrhosis, is a long-term goal of this trial. A second Phase 3 clinical study, MAESTRO-NAFLD-1, has also been initiated. This 52-week non-invasive study in a broader segment of NASH patients will provide additional safety information to support the NASH indication and will include key efficacy endpoints: LDL-cholesterol lowering, triglyceride lowering, reduction of liver fat as determined by MRI-PDFF, as well as reduction of elevated liver enzymes and reduction in fibrosis biomarkers. This is a non-biopsy study in people with NASH, as documented using non-invasive techniques or historical liver biopsy.

Ferring Pharmaceuticals

Ferring Pharmaceuticals, Inc. is a Parsippany, NJ-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Pharmessen Scientific

Pharmessen Scientific, Inc. is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Acadia Pharmaceuticals

Acadia Pharmaceuticals is a biopharmaceutical company that develops and commercializes therapies for central nervous system disorders. Their focus is on developing treatments for dementia-related psychosis, negative symptoms of schizophrenia, and Rett ...